Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P04053

UPID:
TDT_HUMAN

ALTERNATIVE NAMES:
Terminal addition enzyme; Terminal deoxynucleotidyltransferase

ALTERNATIVE UPACC:
P04053; Q53FH1; Q5W103; Q96E50

BACKGROUND:
Terminal addition enzyme, known for its template-independent DNA polymerase activity, is essential in the immune system's development. By catalyzing the random addition of deoxynucleoside triphosphates, it contributes to the genetic diversity necessary for effective immune responses. This enzyme's activity is key in the N region addition during B- and T-cell receptor gene rearrangement.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Terminal addition enzyme offers a pathway to novel therapeutic approaches. Its involvement in the genetic rearrangement processes of the immune system highlights its potential as a therapeutic target for immune-related disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.